Abstract YO27
Case summary
Whole Brain Radiotherapy plays a pivoted role in brain metastases. There is controversy regarding the radiotherapeutics dose fractionation in brain metastasis. 30 Gray in 10 fractions in 2 weeks in the standard regimen in most centers. Regarding the extraordinary poor survival prognosis of patients with brain metastasis, 20 Gray in 5 fractions over 1 week would be preferable. An observational comparative analytical study was conducted in National Academy of Medical Sciences (NAMS) Bir Hospital after ethical approval from the institutional review board of NAMS. Patients were randomized into two group one with 20 Gray in 5 fraction over one week and other with the 30Gray in 10 Fraction over 2 weeks. A total number of 55 patients were enrolled in the study. Assessment of clinical symptoms was done using Common terminology Criteria for Adverse Events (CTCAE), before treatment, just after treatment and 6 weeks of treatment. Response evaluation criteria in solid tumors (RECIST) was used to access the treatment response in terms of local control. Acute toxicity of the patients were assess during treatment and then followed for 6 weeks and graded according to Radiation Therapy Oncology Group (RTOG) acute radiation morbidity scoring. Of the 55 patients enrolled, in 20Gray/5# (n=28) and 30Gray/10# (n=26) groups, all participants in the study received the planned treatment of radiotherapy. Local control with complete or partial response was 63% in 20Gray v 48% in 30Gray (p = 0.722). Six month survival was 29.1% in 20Gray/5# v 23.6% in 30Gray/10# (p = 0.504). Objective Responsive of Headache was 53% v 52% (p= 0.469), vomiting 43% v 55%,(p=0.956),Seizure 11.7% v 3.7% (p = 0.979), focal weakness 21.3% v 4.4% (p=0.249), ataxia1 4.3% v 3.7% (p=0.281), speech disorder 3.5% v 7.4% (p=0.147), acute toxicities of grade 2 and grade 3 were acceptable in both Groups, nausea 9.1% v 9.1% ( p =0.907), vomiting 1.9% v 3.7% (p=0.199) , headache 1.9% v 3.7% (p=0.696) and Dermatitis 5.7% v 5.7% (p =0.140) 20Gray in 5fractions and 30Gray in 10 Fractions are equally effective and feasible as statistically insignificant difference in the response rate and acute toxicities were observed in the two groups
Clinical trial identification
Editorial acknowledgement
Resources from the same session
481P - Updated survival outcomes of the phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small cell lung cancer (KTORG1402)
Presenter: Toshihide Yokoyama
Session: Poster display session
Resources:
Abstract
490P - Outcomes of sequential epidermal growth factor receptor tyrosine (EGFR) tyrosine kinase inhibitor (TKI) therapy in patients with advanced non-small cell lung carcinoma (NSCLC)- a real-world institutional experience
Presenter: Yvonne Ang
Session: Poster display session
Resources:
Abstract
498P - An observational retrospective study to evaluate the incidence of acquired EGFR T790M resistance in NSCLC patients with EGFR mutation following progression after at least one prior EGFR TKI treatment in Taiwan: ARISE study
Presenter: Shang-gin Wu
Session: Poster display session
Resources:
Abstract
501P - Clinical characteristics and efficacy in non-small cell lung cancer patients with EGFR exon 20 insertion and EGFR amplification
Presenter: Xin Gao
Session: Poster display session
Resources:
Abstract
502P - Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced non-small cell lung cancer with uncommon mutations: A multicenter observational study
Presenter: Masaki Kanazu
Session: Poster display session
Resources:
Abstract
482P - Interim analysis from a phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC
Presenter: Filippo De Marinis
Session: Poster display session
Resources:
Abstract
483P - A phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients with EGFR mutation-positive NSCLC: A biomarker analysis
Presenter: Rafael Rosell
Session: Poster display session
Resources:
Abstract
484P - Activity of afatinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC and baseline brain metastases: Pooled analysis of three large phase IIIb trials
Presenter: Maya Gottfried
Session: Poster display session
Resources:
Abstract
491P - Clinical outcomes of leptomeningeal metastases in EGFR-mutant lung adenocarcinoma
Presenter: Chia-I Shen
Session: Poster display session
Resources:
Abstract
510P - Paclitaxel as continuation maintenance therapy in patients with advanced non-small cell lung cancer
Presenter: Suzy Gohar
Session: Poster display session
Resources:
Abstract